Esomeprazole

Nexium treats symptomatic GERD and heals erosive esophagitis (EE), with indication-specific pediatric ages. Adult uses also include maintenance of EE healing, risk reduction of NSAID-associated gastric ulcer in at-risk patients, H. pylori eradication with specified antibiotics to reduce duodenal-ulcer recurrence, and pathological hypersecretory conditions including Zollinger–Ellison syndrome. NSAID-ulcer risk includes age 60 or older or prior gastric ulcer.

Nexium 24HR capsules treat frequent heartburn occurring at least 2 days/week in adults 18 and older; full effect may take 1–4 days. Prescription IV esomeprazole treats GERD with EE when oral therapy is inappropriate from age 1 month, and reduces rebleeding after therapeutic endoscopy of bleeding gastric/duodenal ulcers in adults. These are separate indications.

Take at least 1 hour before a meal. Use the shortest appropriate course and reassess the need to continue. Trial durations are not absolute limits for every patient.

Ages 1 month–11 years use the labeled oral suspension; ages 12–17 years may use capsules or suspension. The infant indication is EE due to acid-mediated GERD, not nonspecific infant reflux symptoms. Weight bands and treatment durations are product-specific; do not infer a dose below the labeled weight band.

Swallow prescription capsules whole, or sprinkle their intact granules onto a tablespoon of cool soft applesauce and swallow immediately without chewing. Suspension packets: mix 2.5/5 mg in 5 mL water, or 10/20/40 mg in 15 mL; wait 2–3 minutes, stir and take within 30 minutes, then rinse remaining granules with water. Feeding-tube administration has distinct label instructions and requires pharmacist review. OTC capsules: one 20-mg capsule whole before morning food daily for 14 days; repeat no more often than every 4 months without clinician direction. OTC use under age 18 needs medical advice.

The oral label lists esomeprazole 40 mg daily plus amoxicillin 1 g twice daily and clarithromycin 500 mg twice daily for 10 days. ACG 2024 advises against empiric clarithromycin triple therapy without demonstrated susceptibility, preferring other regimens such as optimized bismuth quadruple therapy for 14 days. Select a current complete regimen with antibiotic contraindications, interactions and renal adjustment reviewed.

IV EE: adults 20 or 40 mg daily; age 1 month to <1 year 0.5 mg/kg daily; age 1–17 years <55 kg 10 mg or ≥55 kg 20 mg daily. Treat up to 10 days; change to oral when appropriate. Adults may receive injection over ≥3 minutes or infusion over 10–30 minutes; pediatric doses use infusion. Adult post-endoscopy rebleeding: 80 mg over 30 minutes then 8 mg/hour for 71.5 hours. Hepatic impairment reduces the maintenance infusion to 6 mg/hour (Child-Pugh A/B) or 4 mg/hour (C), preserving the 80-mg load. Preparation is a pharmacy task.

Prescription esomeprazole is contraindicated with hypersensitivity to substituted benzimidazoles/components, including prior allergic interstitial nephritis, and with rilpivirine-containing products. Combination antibiotics have their own contraindications. The OTC label says not to use with esomeprazole allergy or specified alarm symptoms; review all prescription medicines before self-treatment.

The selected oral, IV and OTC labels have no boxed warning. Serious hypersensitivity, renal injury and interaction risks remain clinically important.

Headache, abdominal pain, diarrhea, nausea, flatulence or constipation are common oral trial events; pediatric reports include diarrhea, headache and somnolence. Serious postmarketing reactions have uncertain frequency. Excess dosing requires medical or poison-center assessment and supportive care; there is no specific antidote, and high protein binding limits dialysis benefit.

Rilpivirine combinations are contraindicated; avoid nelfinavir, and consult the specific atazanavir/saquinavir labels. Avoid clopidogrel because active-metabolite formation and platelet inhibition decrease; separating doses does not establish safety. Review an alternative treatment with the prescriber.

Monitor INR with warfarin, drug levels with digoxin or tacrolimus, and toxicity with high-dose methotrexate; temporary PPI withdrawal may be considered for the latter. Limit concomitant citalopram to 20 mg/day; consider cilostazol 50 mg twice daily according to its label. Gastric-pH changes can reduce absorption of iron, some azole antifungals, kinase inhibitors or mycophenolate; consult their labels. Avoid rifampin/St. John’s wort. Voriconazole usually needs no esomeprazole adjustment, but high-dose hypersecretory treatment warrants review.

Coordinate holding esomeprazole for at least 14 days before chromogranin A testing and 4 weeks before secretin stimulation testing. PPI-related false-positive urine THC screening requires a confirmatory method. These test-specific instructions differ from the PPI hold before H. pylori eradication testing.

Adequate controlled pregnancy studies with esomeprazole are lacking; epidemiologic omeprazole data have not demonstrated increased major malformation risk, but do not prove every esomeprazole exposure safe. The labels report limited milk information through omeprazole and no clinical infant-effect or milk-production data for esomeprazole. Balance maternal need and breastfeeding benefits; OTC labeling directs consultation.

Prescription EE treatment includes infants from 1 month within the weight bands above. Symptomatic GERD below age 1 year was not shown effective. Pediatric maintenance of EE healing, NSAID-ulcer prevention, H. pylori eradication and hypersecretory uses are not established by this oral label. OTC self-use starts at age 18. Older adults generally need no adjustment solely for age but may need investigation of recurrent or poorly responsive symptoms.

Renal impairment does not require an oral esomeprazole dose adjustment; this does not eliminate interstitial-nephritis risk. Mild/moderate hepatic impairment requires no oral adjustment. In severe impairment, the adult EE-healing maximum is 20 mg daily; the current oral table instead specifies a 20-mg twice-daily starting dose for hypersecretory disease. The label recommends modification for other specified severe-hepatic indications without providing a universal numeric regimen. Review the exact indication rather than applying one cap to all treatment. IV EE in Child-Pugh C is limited to 20 mg daily; post-endoscopy infusion changes are listed above.

The S-isomer of omeprazole inhibits gastric parietal-cell H+/K+-ATPase after activation in the acidic secretory environment. This reduces basal and stimulated acid secretion. It is not a rapid antacid; the OTC product may take several days to reach full benefit.

Hepatic CYP2C19 and CYP3A4 metabolism drives disposition, with variable exposure across metabolizer phenotypes. Less than 1% is excreted unchanged in urine. Severe hepatic impairment increases exposure. Route-specific PK data do not justify replacing a post-endoscopy continuous infusion with an unreviewed oral regimen.

Investigate suboptimal response or early relapse, especially in older adults. Consider baseline and periodic magnesium with prolonged therapy, digoxin or diuretics; monitor calcium in patients at risk for hypocalcemia and assess B12 deficiency if clinically suspected. Check interacting-drug levels/INR when indicated. ACG recommends H. pylori test of cure at least 4 weeks after antibiotics and after withholding PPIs/PCABs for at least 2 weeks, using an appropriate validated test.

Review the exact package directions, meal timing and duration; preserve intact delayed-release granules. Report persistent diarrhea, rash with systemic symptoms, joint pain, reduced kidney function symptoms or alarm features promptly. Keep a list of medicines and supplements and consult before adding OTC Nexium to prescription therapy. Do not duplicate PPIs or continue repeated self-treatment without assessing the reason.

Prescription Nexium 20-mg capsules are amethyst with two yellow cap bars and NEXIUM 20 mg; the 30-capsule bottle is NDC 0186-5020-31. Nexium 24HR 20-mg capsule 14-count carton is NDC 0573-2450-14. The selected Slate Run 40-mg IV powder comes as 10 single-dose vials, NDC 70436-190-82. Other manufacturers and OTC presentations can look different.

Covered prescription forms are magnesium delayed-release capsules 20/40 mg and oral-suspension packets 2.5/5/10/20/40 mg, expressed as esomeprazole. OTC capsules contain 20 mg. The selected sodium IV vial contains 40 mg equivalent. Other OTC tablets, generic oral formulations and alternative products need their own administration instructions.

Rx oral: 25°C, excursions 15–30°C; keep capsule containers tightly closed. OTC capsules: 20–25°C and retain the carton. IV vials: 25°C, excursions 15–30°C, protected from light. Pharmacy preparation must follow section 2 for diluent, concentration, line compatibility and route-specific stability; single-dose vial residue is discarded. Do not infer IV preparation rules from oral packets.